Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.045 AUD
−8.79 M AUD
23.32 M AUD
220.43 M
About NOVA EYE MEDICAL LIMITED
Sector
Industry
CEO
Thomas Spurling
Website
Headquarters
Kent Town
Founded
1970
ISIN
AU0000094252
FIGI
BBG000BT1XB7
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of EYE is 0.150 AUD — it hasn't changed in the past 24 hours. Watch NOVA EYE MEDICAL LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange NOVA EYE MEDICAL LIMITED stocks are traded under the ticker EYE.
EYE stock has risen by 3.45% compared to the previous week, the last month showed zero change in price, over the last year NOVA EYE MEDICAL LIMITED has showed a 18.50% increase.
We've gathered analysts' opinions on NOVA EYE MEDICAL LIMITED future price: according to them, EYE price has a max estimate of 0.48 AUD and a min estimate of 0.48 AUD. Watch EYE chart and read a more detailed NOVA EYE MEDICAL LIMITED stock forecast: see what analysts think of NOVA EYE MEDICAL LIMITED and suggest that you do with its stocks.
EYE stock is 3.33% volatile and has beta coefficient of 1.64. Track NOVA EYE MEDICAL LIMITED stock price on the chart and check out the list of the most volatile stocks — is NOVA EYE MEDICAL LIMITED there?
Today NOVA EYE MEDICAL LIMITED has the market capitalization of 34.36 M, it has increased by 3.45% over the last week.
Yes, you can track NOVA EYE MEDICAL LIMITED financials in yearly and quarterly reports right on TradingView.
NOVA EYE MEDICAL LIMITED is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
EYE net income for the last half-year is −3.17 M AUD, while the previous report showed −5.63 M AUD of net income which accounts for 43.73% change. Track more NOVA EYE MEDICAL LIMITED financial stats to get the full picture.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVA EYE MEDICAL LIMITED EBITDA is −5.98 M AUD, and current EBITDA margin is −25.63%. See more stats in NOVA EYE MEDICAL LIMITED financial statements.
Like other stocks, EYE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVA EYE MEDICAL LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVA EYE MEDICAL LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVA EYE MEDICAL LIMITED stock shows the sell signal. See more of NOVA EYE MEDICAL LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.